Literature DB >> 860138

Naloxone in chronic schizophrenia.

J Volavka, A Mallya, S Baig, J Perez-Cruet.   

Abstract

The specific narcotic antagonist naloxone (0.4 milligram) was given intravenously to seven chronic schizophrenics who reported that they had very frequent auditory hallucinations. Saline solution was used as a placebo. The coded study did not reveal any effect of naloxone on hallucinations or on global psychopathology.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 860138     DOI： 10.1126/science.860138

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  9 in total

1.  Cortical opioid markers in schizophrenia and across postnatal development.

Authors:  David W Volk; Polina V Radchenkova; Erin M Walker; Elizabeth J Sengupta; David A Lewis
Journal:  Cereb Cortex       Date:  2011-08-01       Impact factor: 5.357

2.  Clozapine and some other antipsychotic drugs may preferentially block the same subset of GABA(A) receptors.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

3.  Opioid peptides as neuroregulators: potential areas for the study of genetic-behavioral mechanisms.

Authors:  J D Barchas; S Sullivan
Journal:  Behav Genet       Date:  1982-02       Impact factor: 2.805

4.  The effects of naloxone on methylphenidate-induced mood and behavioral changes: a negative study.

Authors:  L Y Huey; D S Janowsky; L L Judd; N A Roitman; P L Clopton; D Segal; L Hall; D Parker
Journal:  Psychopharmacology (Berl)       Date:  1980-02       Impact factor: 4.530

5.  [On the physiology and pharmacology of endorphins (author's transl)].

Authors:  K Kuschinsky
Journal:  Klin Wochenschr       Date:  1979-07-15

6.  Immunoreactive beta-endorphin and adrenocorticotropin in human cerebrospinal fluid.

Authors:  K Nakao; S Oki; I Tanaka; K Horii; Y Nakai; T Furui; M Fukushima; A Kuwayama; N Kageyama; H Imura
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

Review 7.  New and experimental therapeutic roles for naloxone and related opioid antagonists.

Authors:  L F McNicholas; W R Martin
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

Review 8.  Peptide neuroregulators: the opioid system as a model.

Authors:  J D Barchas; C Evans; G R Elliott; P A Berger
Journal:  Yale J Biol Med       Date:  1985 Nov-Dec

9.  Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials.

Authors:  Samuel D Clark; Jared X Van Snellenberg; Jacqueline M Lawson; Anissa Abi-Dargham
Journal:  Neuropsychopharmacology       Date:  2020-06-09       Impact factor: 7.853
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.